Baird Maintains Medtronic(MDT.US) With Hold Rating, Raises Target Price to $96
Medtronic: Hold Rating Justified by Financial Headwinds and Market Shifts
Truist Financial Maintains Medtronic(MDT.US) With Hold Rating, Raises Target Price to $93
Medtronic Analyst Ratings
Truist Raises Price Target on Medtronic to $93 From $90, Maintains Hold Rating
Morgan Stanley Maintains Medtronic(MDT.US) With Buy Rating, Maintains Target Price $98
Buy Rating on Medtronic: Stable Demand, Margin Improvement, and Strategic Positioning Fuel Optimistic Outlook
RBC Capital Upgrades Medtronic(MDT.US) to Buy Rating, Raises Target Price to $105
Medtronic Is Maintained at Sector Perform by RBC Capital
Medtronic Analyst Ratings
RBC Capital Maintains Medtronic(MDT.US) With Hold Rating, Raises Target Price to $98
Bernstein Maintains Medtronic(MDT.US) With Buy Rating, Maintains Target Price $96
Bernstein Sticks to Its Buy Rating for Medtronic (MDT)
Goldman Sachs Adjusts Price Target on Medtronic to $84 From $82
Evercore Maintains Medtronic(MDT.US) With Buy Rating, Raises Target Price to $104
Medtronic Is Maintained at Neutral by Citigroup
Medtronic Analyst Ratings
Citi Maintains Medtronic(MDT.US) With Hold Rating, Announces Target Price $92
TD Cowen Maintains Medtronic(MDT.US) With Buy Rating, Maintains Target Price $95
Medtronic's Buy Rating Justified by Growth in CST Sector and AiBLE's Market Integration